Global Orphan Diseases Partnering 2010-2017: Deal trends, players and financials

Publisher Name :
Date: 01-Feb-2017
No. of pages: 250

"Delivery of this report will take 1-3 days after purchase."

Summary

The Global Orphan Diseases Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies

Description

Global Orphan Diseases Partnering 2010 to 2017 provides the full collection of Orphan Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Orphan Diseases partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Orphan Diseases partnering agreement structure

Orphan Diseases partnering contract documents

Top Orphan Diseases deals by value

Most active Orphan Diseases dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.

The report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Orphan Diseases dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Orphan Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Orphan Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Orphan Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Orphan Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Orphan Diseases partnering deals by specific Orphan Diseases target announced since 2010. The chapter is organized by specific Orphan Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Orphan Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Orphan Diseases partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Orphan Diseases technologies and products.

Report scope

Global Orphan Diseases Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Orphan Diseases trends and structure of deals entered into by leading companies worldwide.

Global Orphan Diseases Partnering 2010 to 2017 includes:

Trends in Orphan Diseases dealmaking in the biopharma industry since 2010

Analysis of Orphan Diseases deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Orphan Diseases deal contract documents

Comprehensive access to over 3500 Orphan Diseases deal records

The leading Orphan Diseases deals by value since 2010

Most active Orphan Diseases dealmakers since 2010

In Global Orphan Diseases Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Orphan Diseases Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 100 orphan diseases deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Orphan Diseases Partnering 2010 to 2017 provides the reader with the following key benefits:

In-depth understanding of Orphan Diseases deal trends since 2010

Access Orphan Diseases deal headline, upfront, milestone and royalty data

Research hundreds of actual contracts between Orphan Diseases partner companies

Comprehensive access to over 750 links to actual Orphan Diseases deals entered into by the world's biopharma companies

Indepth review of Orphan Diseases deals entered into by the top 25 most active dealmakers

Benchmark the key deal terms companies have agreed in previous deals

Identify key terms under which companies partner Orphan Diseases opportunities

Uncover companies actively partnering Orphan Diseases opportunities

Global Orphan Diseases Partnering 2010-2017: Deal trends, players and financials

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Orphan Diseases dealmaking
2.1. Introduction
2.2. Orphan Diseases partnering over the years
2.3. Orphan Diseases partnering by deal type
2.4. Orphan Diseases partnering by industry sector
2.5. Orphan Diseases partnering by stage of development
2.6. Orphan Diseases partnering by technology type
2.7. Orphan Diseases partnering by therapeutic indication

Chapter 3 -Financial deal terms for Orphan Diseases partnering
3.1. Introduction
3.2. Disclosed financials terms for Orphan Diseases partnering
3.3. Orphan Diseases partnering headline values
3.4. Orphan Diseases deal upfront payments
3.5. Orphan Diseases deal milestone payments
3.6. Orphan Diseases royalty rates

Chapter 4 - Leading Orphan Diseases deals and dealmakers
4.1. Introduction
4.2. Most active in Orphan Diseases partnering
4.3. List of most active dealmakers in Orphan Diseases
4.4. Top Orphan Diseases deals by value

Chapter 5 - Orphan Diseases contract document directory
5.1. Introduction
5.2. Orphan Diseases partnering deals where contract document available

Chapter 6 - Orphan Diseases dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Orphan Diseases therapeutic target
Appendices
Appendix 1 - Directory of Orphan Diseases deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Orphan Diseases deals by deal type 2010 to 2017
Appendix 3 - Directory of Orphan Diseases deals by stage of development 2010 to 2017
Appendix 4 - Directory of Orphan Diseases deals by technology type 2010 to 2017
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Figures

Figure 1: Orphan Diseases partnering since 2010
Figure 2: Orphan Diseases partnering by deal type since 2010
Figure 3: Orphan Diseases partnering by industry sector since 2010
Figure 4: Orphan Diseases partnering by stage of development since 2010
Figure 5: Orphan Diseases partnering by technology type since 2010
Figure 6: Orphan Diseases partnering by indication since 2010
Figure 7: Orphan Diseases deals with a headline value
Figure 8: Orphan Diseases deals with upfront payment values
Figure 9: Orphan Diseases deals with milestone payment
Figure 10: Orphan Diseases deals with royalty rates
Figure 11: Active Orphan Diseases dealmaking activity- 2010 to 2017
Figure 12: Top Orphan Diseases deals by value since 2010
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • North America Drugs for Schistosomiasis Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 20-Feb-2017        Price: US 4480 Onwards        Pages: 120
    Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.Scope of the Report:This rep......
  • Seasonal Influenza Vaccination Market in Lithuania, Estonia, Latvia (Baltic Countries) By (Child & Adult) Forecast
    Published: 20-Feb-2017        Price: US 1200 Onwards        Pages: 71
    Seasonal Influenza Vaccination Market in Lithuania, Estonia, Latvia (Baltic Countries) By (Child & Adult) Forecast report published by Renub Research. According to this report, in the Baltic Countries, Lithuania is having the highest seasonal influenza vaccine market share followed by Latvia and Estonia. In terms of children vaccination, Lithuania & Latvia hold nearly 70 percent market share in 2016 whereas, in adult vaccination segments, these two will share more than 95 percent market share by......
  • Global Drugs for Schistosomiasis Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 20-Feb-2017        Price: US 3480 Onwards        Pages: 120
    Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.Scope of the Report:This rep......
  • Global Prostacyclin Market Research Report 2017
    Published: 14-Feb-2017        Price: US 2900 Onwards        Pages: 103
    Notes: Production, means the output of Prostacyclin Revenue, means the sales value of Prostacyclin This report studies Prostacyclin in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer, covering - Actelion Pharmaceuticals - United Therapeutics Corporation - Gilead - Bayer ......
  • Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2017
    Published: 13-Feb-2017        Price: US 2250 Onwards        Pages: 149
    DelveInsight's, "Immune Checkpoints Activators- Competitive Landscape, Technology and Pipeline Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Immune Checkpoints Activators. This report provides information on the therapeutic development based on Immune Checkpoints Activators mechanism of action dealing w......
  • Global Calcitriol (CAS 32222-06-3) Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 11-Feb-2017        Price: US 3480 Onwards        Pages: 116
    Calcitriol is a white, crystalline compound which occurs naturally in humans. It has a calculated molecular weight of 416.65 and is soluble in organic solvents but relatively insoluble in water. Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. The report focus on the Calcitriol formulations market survey.Scope of the Report:This report focuses on the Ca......
  • Europe Calcitriol (CAS 32222-06-3) Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 11-Feb-2017        Price: US 4480 Onwards        Pages: 116
    Calcitriol is a white, crystalline compound which occurs naturally in humans. It has a calculated molecular weight of 416.65 and is soluble in organic solvents but relatively insoluble in water. Calcitriol is a synthetic vitamin D analog which is active in the regulation of the absorption of calcium from the gastrointestinal tract and its utilization in the body. The report focus on the Calcitriol formulations market survey.Scope of the Report:This report focuses on the Ca......
  • EMEA Inhalation & Nasal Spray Generic Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2022
    Published: 09-Feb-2017        Price: US 4480 Onwards        Pages: 121
    Generic drugs are drugs that are not associated with any company or a brand name and are subject to regulation of countries where they are dispensed. According to US FDA, A generic drug is identical--or bioequivalent--to a brand name drug in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use.Inhalation & Nasal Spray is a kind of drug used to relieve sneezing, runny, stuffy, or itchy nose and itchy, watery eyes caused by hay fever or o......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Paracetamol Market 2017 Forecast to 2022
    Published: 09-Feb-2017        Price: US 4880 Onwards        Pages: 116
    Paracetamol, also named acetaminophen, is an active ingredient in hundreds of over-the-counter (OTC) and prescription medicines. It relieves pain and fever. And, it is also combined with other active ingredients in medicines that treat allergy, cough, colds, flu, and sleeplessness.In prescription medicines, acetaminophen is found with other active ingredients to treat moderate to severe pain. Acetaminophen can cause serious liver damage if more than directed is used.Scope of the Re......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs